# Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

> **NCT05113693** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 33 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** CKD-393
- **DRUG:** CKD-501, D759, H053

## Key facts

- **NCT ID:** NCT05113693
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-25
- **Primary completion:** 2021-12-06
- **Final completion:** 2021-12-10
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113693, "Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05113693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*